Biosimilar Solutions Initiates Registrational Clinical Trial for Biosimilar Version Neulasta AGUADILLA, Puerto Rico, April 13, 2022 (GLOBE NEWSWIRE) -- OcyonBio, LLC's client Biosimilar Solutions, Inc., announces it has started its registrational clinical trials for the biosimilar version...

OcyonBio Client Biosimilar Solutions, Inc. Initiates Registrational Clinical Trial for Its First Biosimilar Product AGUADILLA, Puerto Rico, March 23, 2022 (GLOBE NEWSWIRE) -- Biosimilar Solutions, Inc. announces it has started its registrational clinical trials for BSC1020®, a recombinant filgrastim product...

OcyonBio Announces Biosimilar Solutions to Begin GMP Manufacturing in Puerto Rico AGUADILLA, Puerto Rico, March 14, 2022 (GLOBE NEWSWIRE) -- OcyonBio announces manufacturing and operations agreement to develop biosimilar drug product facilities for Biosimilar Solutions, Inc....

OcyonBio Appoints Ricardo Zayas as Chief Operating Officer AGUADILLA, Puerto Rico, Feb. 14, 2022 (GLOBE NEWSWIRE) -- OcyonBio, LLC announces it has appointed Ricardo Zayas its Chief Operating Officer. OcyonBio is creating an advanced therapy contract...

OcyonBio Appoints Daniel Chang, CPA, MBA, CPMP, CPIM as Chief Financial Officer AGUADILLA, Puerto Rico, Jan. 25, 2022 (GLOBE NEWSWIRE) -- OcyonBio, LLC announces it has appointed Daniel Chang Chief Financial Officer. OcyonBio is creating a contract development and manufacturing...